GE Healthcare Technologies Hits New 52-Week Low at $58.75

GE Healthcare Technologies, Inc. has reached a new 52-week low, trading at USD 58.75 as of April 29, 2026. This marks a significant decline for the mid-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, GE Healthcare has experienced a performance drop of 21.5%, contrasting sharply with the S&P 500's gain of 28.33%. The company's market capitalization stands at approximately USD 32.89 billion, with a price-to-earnings (P/E) ratio of 15.00. Despite the recent price decline, GE Healthcare maintains a return on equity of 20.79%, indicating strong management efficiency. The company also demonstrates a solid ability to manage its debt, reflected in a debt-to-equity ratio of 0.54 and a low debt-to-EBITDA ratio of 2.11 times. In terms of valuation, GE Healthcare's price-to-book ratio is 3.17, and it offers a modest dividend yield of 0.10%. However, the stock has consistently underperformed against the S&P 500 over the last three years, raising questions about its market position and future performance.